Business Context and Reporting Period
This Form 8-K Current Report was filed by Chemomab Therapeutics Ltd. on June 14, 2023. The report details the formal approval of compensation terms for Ms. Sigal Fattal, who was previously appointed as Chief Financial Officer (CFO) on June 1, 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
Material Changes
The primary material change reported is the Board's approval of specific compensation terms for the newly appointed CFO, Ms. Sigal Fattal, effective June 14, 2023.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or general management commentary regarding business operations. It details the following specific compensation components approved for the CFO:
- Base Salary: $260,000 annually (excluding customary social benefits).
- Bonus Potential: Up to 45% of the annual base salary, contingent on mutually agreeable objectives and Compensation Committee approval.
- Equity Grant: Options to purchase 102,860 American Depositary Shares (ADS) at an exercise price of $1.70 per ADS.
- Vesting and Terms: Options vest over four years. They include acceleration upon a Change in Control (CIC) and an extended 12-month exercise period post-termination following a CIC, except in cases of termination for Cause.
Investor Verification Checklist
- Verify the total number of outstanding options granted to Ms. Fattal (102,860 ADS) against the company's total authorized share pool.
- Confirm the exercise price of $1.70 relative to the market price of the ADS on the grant date.
- Review the specific performance objectives required to achieve the 45% bonus potential in future filings or proxy statements.
- Monitor the vesting schedule to ensure the four-year timeline aligns with the company's equity incentive plan.